Platelet-activating Factor and Normal or Leukaemic Haematopoiesis
Overview
Affiliations
Platelet-activating factor (PAF), a phospholipid mediator with a wide range of actions on mature leukocytes, acts directly during early human haematopoiesis by affecting the growth of haematopoietic progenitors and indirectly, by modulating cytokine synthesis by bone marrow stromal cells. At this time, its role during leukaemic diseases remains speculative. The lack of membrane PAF receptor (PAF-R) on leukaemic blasts suggest that this receptor represents a marker of mature cells and its membrane induction a consequence of cell maturation. While the couple PAF/PAF-R has been largely studied using B cell lines, few results are available using B cells of patients with haematopoietic malignancies casting some doubts concerning the potential role (if any) of this molecule during leukaemic diseases.
Oncul S, Cho M Cancers (Basel). 2023; 15(4).
PMID: 36831623 PMC: 9953912. DOI: 10.3390/cancers15041282.
In vivo RNAi screening identifies as a target for combination therapy with TKIs in BCP-ALL.
Fiedler E, Bhutkar A, Lawler E, Besada R, Hemann M Blood Adv. 2018; 2(11):1229-1242.
PMID: 29853524 PMC: 5998924. DOI: 10.1182/bloodadvances.2017015610.
da Silva Junior I, Stone S, Rossetti R, Jancar S, Lepique A J Immunol Res. 2018; 2017:5482768.
PMID: 29445756 PMC: 5763242. DOI: 10.1155/2017/5482768.
Lu W, Jia D, An S, Mu M, Qiao X, Liu Y Sci Rep. 2017; 7(1):8402.
PMID: 28827748 PMC: 5566473. DOI: 10.1038/s41598-017-08970-3.
Lipid mediators and human leukemic blasts.
Fiancette R, Vincent-Fabert C, Guerin E, Trimoreau F, Denizot Y J Oncol. 2010; 2011.
PMID: 20953410 PMC: 2952803. DOI: 10.1155/2011/389021.